Table 2.

Summary of adverse events considered possibly related to study drug (in ≥2 patients in overall population)

Preferred term	Overall AEs (N = 12)	150 mg LY3023414 (n = 3)		200 mg LY3023414 (n = 9)
	Any grade	n (%)		n (%)
	n (%)	Any grade	Grade ≥ 3	Any grade	Grade ≥ 3
Stomatitis	9 (75.0)	2 (66.7)	0	7 (77.8)	2 (22.2)
Nausea	8 (66.7)	2 (66.7)	0	6 (66.7)	0
Appetite decreased	7 (58.3)	1 (33.3)	0	6 (66.7)	0
Diarrhea	5 (41.7)	1 (33.3)	0	4 (44.4)	0
Anemia	5 (41.7)	2 (66.7)	1 (33.3)	3 (33.3)	1 (11.1)
Fatigue	4 (33.3)	2 (66.7)	0	2 (22.2)	0
Hyperglycemia	4 (33.3)	2 (66.7)	1 (33.3)	2 (22.2)	1 (11.1)
Hypophosphatemia	4 (33.3)	1 (33.3)	0	3 (33.3)	2 (22.2)
Proteinuria	4 (33.3)	1 (33.3)	0	3 (33.3)	0
Vomiting	4 (33.3)	1 (33.3)	0	3 (33.3)	0
Blood creatinine increased	4 (33.3)	1 (33.3)	0	3 (33.3)	0
ALT increased	3 (25.0)	1 (33.3)	0	2 (22.2)	0
AST increased	3 (25.0)	0	0	3 (33.3)	0
Rash	3 (25.0)	1 (33.3)	0	2 (22.2)	0
Pruritis	3 (25.0)	1 (33.3)	0	2 (22.2)	0
Hypokalemia	2 (16.7)	1 (33.3)	0	1 (11.1)	0
Hypotension	2 (16.7)	0	0	2 (22.2)	0
Pyrexia	2 (16.7)	0	0	2 (22.2)	0
Weight decreased	2 (16.7)	1 (33.3)	0	1 (11.1)	0
Hematological AEs
Platelet count decreased	5 (41.7)	2 (66.7)	0	3 (33.3)	0
WBC count decreased	2 (16.7)	0	0	2 (22.2)	0

AEs adverse events, ALT alanine aminotransferase, AST aspartate aminotransferase, N number of patients in safety population, n number of patients in the specified category, WBC white blood cell